XERS Stock Price, Xeris Pharmaceuticals Quote, Chart

Market Summary

USD1.77-0.01

Market Closed

-0.56%

XERS Stock Price

View Fullscreen

XERS RSI Chart

XERS Valuation

Market Cap

250.0M

Price/Earnings (Trailing)

-4.02

Price/Sales (Trailing)

1.53

Price/Free Cashflow

-5.32

XERS Price/Sales (Trailing)

XERS Profitability

Return on Equity

917.94%

Return on Assets

-19.3%

Free Cashflow Yield

-18.81%

XERS Fundamentals

XERS Revenue

Revenue (TTM)

163.9M

Rev. Growth (Yr)

33.93%

Rev. Growth (Qtr)

-8.13%

XERS Earnings

Earnings (TTM)

-62.3M

Earnings Growth (Yr)

-3.56%

Earnings Growth (Qtr)

-9.85%

Breaking Down XERS Revenue

Last 7 days

-1.1%

Last 30 days

-15.2%

Last 90 days

-24.6%

Trailing 12 Months

-22.3%

How does XERS drawdown profile look like?

XERS Financial Health

Current Ratio

1.64

Debt/Equity

-28.15

Debt/Cashflow

-0.25

XERS Investor Care

Shares Dilution (1Y)

1.57%

Diluted EPS (TTM)

-0.45

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	121.4M	134.1M	152.7M	163.9M
2022	63.5M	79.9M	98.5M	110.2M
2021	27.7M	35.0M	42.3M	49.6M
2020	0	0	0	20.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Xeris Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 18, 2024	johnson john	acquired	429,044	1.99	215,600	-
Mar 15, 2024	kong garheng	acquired	-	-	6,474	-
Mar 15, 2024	johnson john	acquired	-	-	89,571	-
Mar 15, 2024	sherman jeffrey w	acquired	-	-	6,502	-
Mar 14, 2024	schmid john p.	bought	9,720	2.16	4,500	-
Jan 31, 2024	edick paul r	acquired	-	-	1,500,000	see remarks
Jan 31, 2024	johnson kenneth erland	acquired	-	-	175,000	see remarks
Jan 31, 2024	pieper steven	acquired	-	-	450,000	see remarks
Jan 31, 2024	hecht beth	acquired	-	-	750,000	see remarks
Jan 31, 2024	shannon john patrick jr	acquired	-	-	750,000	see remarks

Which funds bought or sold XERS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	BFSG, LLC	unchanged	-	-280	4,420	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-75.75	-35,000	10,000	-%
Apr 23, 2024	Global Retirement Partners, LLC	unchanged	-	-181	913	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	34,906	167,407	-%
Apr 19, 2024	Cutler Group LLC / CA	sold off	-100	-1,000	-	-%
Apr 19, 2024	Veery Capital, LLC	added	12.91	1,823	31,301	0.01%
Apr 18, 2024	Allspring Global Investments Holdings, LLC	added	111	388	780	-%
Apr 18, 2024	Diversified Trust Co	added	12.91	22,612	388,389	0.01%
Apr 17, 2024	DELTEC ASSET MANAGEMENT LLC	reduced	-79.94	-494,308	114,920	0.02%
Apr 16, 2024	TSFG, LLC	new	-	2,000	2,000	-%

Are Funds Buying or Selling XERS?

Are funds buying XERS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own XERS

No. of Funds

Unveiling Xeris Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	stonepine capital management, llc	4.3%	5,937,000	SC 13G/A
Feb 13, 2024	vanguard group inc	5.13%	7,086,345	SC 13G
Jan 26, 2024	blackrock inc.	7.2%	10,011,391	SC 13G
Feb 14, 2023	caxton corp	4.4%	5,973,324	SC 13G/A
Feb 13, 2023	stonepine capital management, llc	8.2%	11,195,189	SC 13G/A
Feb 10, 2023	blackrock inc.	6.3%	8,576,213	SC 13G
Feb 11, 2022	flynn james e	2.05%	2,614,379	SC 13G/A
Jul 12, 2021	blackrock inc.	2.5%	1,684,166	SC 13G
Mar 17, 2021	flynn james e	985%	5,526,709	SC 13G
Feb 16, 2021	redmile group, llc	4.9%	2,397,441	SC 13G/A

Recent SEC filings of Xeris Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
Apr 23, 2024	ARS	ARS
Apr 23, 2024	DEF 14A	DEF 14A
Apr 23, 2024	DEFA14A	DEFA14A
Apr 11, 2024	4	Insider Trading
Apr 01, 2024	4	Insider Trading
Apr 01, 2024	4	Insider Trading
Mar 18, 2024	4	Insider Trading
Mar 14, 2024	4	Insider Trading
Mar 06, 2024	8-K	Current Report
Mar 06, 2024	10-K	Annual Report

Peers (Alternatives to Xeris Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	2.33%	-21.90%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-0.30%	-28.67%	-41.14	9.91	76.23%	61.08%
BMRN	17.2B	2.4B	8.14%	-4.26%	102.64	7.11	15.42%	18.43%
INCY	11.6B	3.7B	-9.39%	-31.39%	19.44	3.14	8.87%	75.42%
MID-CAP
APLS	5.9B	396.6M	-12.04%	-45.12%	-11.11	14.81	425.83%	18.94%
BBIO	4.5B	-	-13.93%	67.39%	-6.85	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-9.40%	-0.33%	-14.47	12.79	440.80%	-27.84%
ARWR	2.9B	240.7M	-12.61%	-20.79%	-9.93	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-6.74%	-16.88%	-45.01	3.8	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-6.36%	-10.84%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-10.64%	-48.02%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	8.01%	271.09%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-10.76%	0.48%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	76.15%	62.71%	-0.24	2.14	-13.45%	66.37%

Xeris Pharmaceuticals Inc News

Latest updates

Xeris Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)														(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Revenue	-8.1%	44.00	48.00	38.00	33.00	33.00	30.00	25.00	22.00	21.00	11.00	9.00	8.00	9.00	9.00
Operating Expenses	1.9%	54.00	53.00	54.00	46.00	48.00	49.00	44.00	51.00	70.00	35.00	35.00	25.00	-	20.00
S&GA Expenses	0.8%	38.00	37.00	38.00	34.00	34.00	34.00	33.00	36.00	54.00	27.00	26.00	19.00	-	16.00
R&D Expenses	26.8%	6.00	5.00	6.00	5.00	5.00	6.00	4.00	6.00	10.00	6.00	5.00	4.00	-	4.00
Interest Expenses	3.8%	7.00	7.00	7.00	6.00	4.00	4.00	3.00	4.00	2.00	2.00	2.00	2.00	-	2.00
Income Taxes	30.2%	-0.24	-0.34	-0.67	-	-0.34	-0.34	-0.34	-0.41	-	-	-	-	-	-
Net Income	-9.9%	-13.39	-12.19	-19.84	-16.83	-12.93	-21.83	-26.18	-33.71	-50.79	-26.01	-27.51	-18.41	-21.86	-16.00
Net Income Margin	6.2%	-0.38*	-0.40*	-0.53*	-0.64*	-0.86*	-1.34*	-1.71*	-2.17*	-2.47*	-2.22*	-2.39*	-2.90*	-4.46*	-
Free Cashflow	151.1%	7.00	-14.61	-13.87	-26.27	-16.25	-17.89	-20.74	-48.54	-29.08	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet											(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2020Q4
Assets	-1.6%	323	328	329	321	345	303	319	338	304	131	159
Current Assets	-1.1%	156	158	156	166	187	149	161	178	143	124	152
Cash Equivalents	46.2%	67.00	46.00	46.00	51.00	122	84.00	95.00	104	67.00	59.00	38.00
Inventory	1.8%	39.00	38.00	37.00	29.00	25.00	20.00	18.00	17.00	18.00	14.00	8.00
Net PPE	-3.5%	6.00	6.00	7.00	6.00	6.00	6.00	6.00	6.00	7.00	7.00	7.00
Goodwill	0%	23.00	23.00	23.00	23.00	23.00	23.00	23.00	23.00	23.00	23.00	-
Liabilities	1.7%	329	324	315	291	299	248	245	241	209	134	125
Current Liabilities	9.4%	95.00	87.00	80.00	81.00	74.00	69.00	65.00	66.00	79.00	37.00	28.00
Long Term Debt	0.3%	191	190	188	188	187	139	138	138	88.00	88.00	87.00
Shareholder's Equity	-275.5%	-6.78	4.00	14.00	30.00	45.00	55.00	74.00	96.00	95.00	-	34.00
Retained Earnings	-2.2%	-617	-603	-591	-571	-554	-541	-520	-493	-460	-409	-337
Additional Paid-In Capital	0.4%	610	608	605	602	600	597	594	590	555	407	371
Shares Outstanding	0.0%	138	138	138	137	136	136	135	135	125	66.00	43.00
Float	-	-	-	362	-	-	-	209	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)														(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Cashflow From Operations	151.1%	7,471	-14,610	-13,744	-26,140	-16,119	-17,754	-20,609	-48,409	-28,946	-22,611	-20,022	-23,956	-	-
Share Based Compensation	12.6%	2,767	2,457	2,928	2,564	2,766	2,941	3,152	3,301	2,743	3,665	2,512	2,461	-	-
Cashflow From Investing	1.5%	14,868	14,655	8,452	-43,979	9,168	6,709	11,868	6,716	36,602	18,505	16,556	26,301	-	-
Cashflow From Financing	-1613.9%	-1,234	-72.00	556	-863	49,156	-187	310	78,194	125	1.00	460	26,661	-	-

XERS Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Total revenue	$ 163,914	$ 110,248	$ 49,590
Costs and expenses:
Cost of goods sold	28,645	22,634	13,318
Research and development	22,341	20,966	25,160
Selling, general and administrative	146,095	137,745	125,718
Amortization of intangible assets	10,843	10,843	550
Total costs and expenses	207,924	192,188	164,746
Loss from operations	(44,010)	(81,940)	(115,156)
Other income (expense):
Interest and other income	4,751	2,578	313
Loss on debt extinguishment, net	(2,837)	(1,223)	0
Interest expense	(26,609)	(14,102)	(7,180)
Change in fair value of warrants	1	1,760	(702)
Change in fair value of contingent value rights	5,200	(3,157)	0
Total other expense	(19,494)	(14,144)	(7,569)
Net loss before benefit from income taxes	(63,504)	(96,084)	(122,725)
Benefit from income taxes	1,249	1,424	0
Net loss	(62,255)	(94,660)	(122,725)
Other comprehensive loss, net of tax:
Unrealized gains (losses) on investments	(2)	7	(38)
Foreign currency translation adjustments	0	1	1
Comprehensive loss	$ (62,257)	$ (94,652)	$ (122,762)
Net loss per common share - basic (in dollars per share)	$ (0.45)	$ (0.70)	$ (1.55)
Net loss per common share - Diluted (in dollars per share)	$ (0.45)	$ (0.70)	$ (1.55)
Weighted Average Number of Shares Issued, Basic			79,027,062
Weighted average common shares outstanding - basic (in shares)	137,674,857	135,628,721
Weighted average common shares outstanding - Diluted (in shares)	137,674,857	135,628,721	79,027,062
Product revenue, net
Total revenue	$ 153,364	$ 109,263	$ 49,280
Royalty, contract and other revenue
Total revenue	$ 10,550	$ 985	$ 310

XERS Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current Assets
Cash and cash equivalents	$ 67,449,000	$ 121,966,000
Short-term investments	5,002,000	0
Trade accounts receivable, net	39,197,000	30,830,000
Inventory	38,838,000	24,735,000
Prepaid expenses and other current assets	5,778,000	9,287,000
Total current assets	156,264,000	186,818,000
Property and equipment, net	5,971,000	5,516,000
Operating lease right-of-use assets	23,204,000	3,992,000
Goodwill	22,859,000	22,859,000
Other assets	109,764,000	120,607,000
Other assets	4,540,000	4,730,000
Total assets	322,602,000	344,522,000
Current Liabilities
Accounts payable	11,565,000	4,606,000
Current operating lease liabilities	3,495,000	1,580,000
Other accrued liabilities	23,510,000	36,786,000
Accrued trade discounts and rebates	22,149,000	16,818,000
Accrued returns reserve	14,198,000	11,173,000
Current portion of contingent value rights	19,109,000	0
Other current liabilities	1,167,000	2,658,000
Total current liabilities	95,193,000	73,621,000
Long-term debt, net of unamortized debt issuance costs	190,932,000	187,075,000
Non-current operating lease liabilities	34,764,000	9,402,000
Non-current contingent value rights	1,379,000	25,688,000
Deferred tax liabilities	2,268,000	3,518,000
Other liabilities	4,848,000	31,000
Total liabilities	329,384,000	299,335,000
Commitments and contingencies (Note 18)
Stockholders' Equity
Preferred stock—par value $0.0001, 25,000,000 shares and 25,000,000 shares authorized and no shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively	0	0
Common stock—par value $0.0001, 350,000,000 shares and 350,000,000 shares authorized as of December 31, 2023 and December 31, 2022, respectively; 138,130,715 and 136,273,090 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively	14,000	14,000
Additional paid in capital	610,254,000	599,966,000
Accumulated deficit	(617,025,000)	(554,770,000)
Accumulated other comprehensive loss	(25,000)	(23,000)
Total stockholders’ equity (deficit)	(6,782,000)	45,187,000
Total liabilities and stockholders’ equity (deficit)	$ 322,602,000	$ 344,522,000

About Xeris Pharmaceuticals Inc

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company markets Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

CEO	Mr. Paul R. Edick
WEBSITE	xerispharma.com
INDUSTRY	Biotechnology
EMPLOYEES	355

Xeris Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Xeris Pharmaceuticals Inc? What does XERS stand for in stocks?

XERS is the stock ticker symbol of Xeris Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Xeris Pharmaceuticals Inc (XERS)?

As of Tue Apr 23 2024, market cap of Xeris Pharmaceuticals Inc is 250.01 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of XERS stock?

You can check XERS's fair value in chart for subscribers.

What is the fair value of XERS stock?

You can check XERS's fair value in chart for subscribers. The fair value of Xeris Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Xeris Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for XERS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Xeris Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether XERS is over valued or under valued. Whether Xeris Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Xeris Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for XERS.

What is Xeris Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, XERS's PE ratio (Price to Earnings) is -4.02 and Price to Sales (PS) ratio is 1.53. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. XERS PE ratio will change depending on the future growth rate expectations of investors.